Quality Improvement Initiative Improving Healthcare Delivery in Immuno-Oncology
Meeting Series
Meeting Series

Quality Improvement Initiative Improving Healthcare Delivery in Immuno-Oncology

A Global Quality Improvement Initiative

Not a member of My prIME? Join now for instant access.

Discuss issues related to quality improvement with an expert. These collaborative calls will give you the opportunity hear from the experts on starting a quality improvement initiative, establishing appropriate quality measures, building a QI team, and dealing with quality improvement challenges.

IME

IME

Getting Started in Quality Improvement—EU Call

26 September 2018
19.00 Central European Time

Register Now

Joseph Jacobson, MD
Chief Quality Officer
Dana Farber Cancer Institute
Boston, Massachusetts, United States

Getting Started in Quality Improvement—US Call

September 27, 2018
7.00 PM Eastern Standard Time

Register Now

Joseph Jacobson, MD
Chief Quality Officer
Dana Farber Cancer Institute
Boston, Massachusetts, United States

Faculty

  • Joseph Jacobson, MDChief Quality Officer
    Dana Farber Cancer Institute
    Boston, Massachusetts, United States

The target audience for this initiative is physicians, physician assistants, nurse practitioners, registered nurses, and other healthcare providers who provide care for patients with cancer in North America and the European Union, including Switzerland and Israel.

After successful completion of this educational activity, participants should be able to:
  • Develop optimum treatment strategies using checkpoint inhibitors to treat a variety of tumor types
  • Create approaches to monitor and manage immune-related adverse events (irAEs) resulting from treatment with immune checkpoint inhibitors
  • Discuss best practices related to shared decision making in clinical practice
  • Describe foundational principles of quality improvement as they relate to healthcare

This curriculum is in collaboration with RealCME. For more information on RealCME, please visit their website at www.healthcourse.com/cme-providers/.

These activities are supported by educational grants from Bristol-Myers Squibb, EMD Serono, and Pfizer.

Independent Medical Education (IME)

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

These activities are provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Disclosures

Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.